Trial Profile
A Phase 1 Multi-Center, Dose-Escalation Study of Vonapanitase Administered Percutaneously to the Superficial Femoral or Popliteal Artery in Patients With Peripheral Artery Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vonapanitase (Primary)
- Indications Peripheral arterial disorders
- Focus Adverse reactions
- Sponsors Proteon Therapeutics
- 30 Apr 2019 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 19 Apr 2019 Planned End Date changed from 1 Dec 2019 to 30 Apr 2019.
- 19 Apr 2019 Planned primary completion date changed from 1 Dec 2019 to 30 Apr 2019.